TLSIW TriSalus Life Sciences, Inc.

Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001826667
AI RATING
STRONG_SELL
85% Confidence

Investment Thesis

TriSalus demonstrates strong revenue growth (53.4% YoY) and exceptional gross margins (84.6%), indicating market traction for its products. However, the company faces critical fundamental solvency challenges: negative stockholders equity (-$33.9M), severe operating losses (-$26.9M), and negative operating cash flow (-$18.0M) create an unsustainable financial position. With limited cash runway of approximately 12-13 months at current burn rates, the company's viability depends on dramatic operational improvement or immediate capital infusion.

Strengths

  • + Strong YoY revenue growth of 53.4% demonstrates market demand and product adoption
  • + Exceptional gross margin of 84.6% indicates superior product quality and pricing power
  • + Adequate short-term liquidity with current ratio of 2.80x provides near-term operational flexibility

Risks

  • ! Negative stockholders equity of -$33.9M represents technical insolvency with liabilities exceeding assets by $33.9M
  • ! Severe cash burn with -$18.9M free cash flow annually against only $20.4M cash position creates existential runway risk
  • ! Unprofitable operations with -$59.7% operating margin and -30.6x interest coverage indicate fundamentally unsustainable business model at current scale

Key Metrics to Watch

Financial Metrics

Revenue
45.2M
Net Income
-39.2M
EPS (Diluted)
$-1.84
Free Cash Flow
-18.9M
Total Assets
35.3M
Cash
20.4M

Profitability Ratios

Gross Margin 84.6%
Operating Margin -59.7%
Net Margin -86.9%
ROE N/A
ROA -111.0%
FCF Margin -41.9%

Balance Sheet & Liquidity

Current Ratio
2.80x
Quick Ratio
2.54x
Debt/Equity
N/A
Debt/Assets
195.8%
Interest Coverage
-30.62x
Long-term Debt
33.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-17T13:39:31.085192 | Data as of: 2025-12-31 | Powered by Claude AI